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number of comorbidities were all significant predictors
accounting for 26% of variance in costs. Number of co-
morbidities was the only variable significantly associated
with the cost of antibiotics. CONCLUSIONS: Appropri-
ate empirical antibiotic treatment of patients with culture
positive intra-abdominal infection is strongly associated
with length of stay and hospital costs.
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OBJECTIVES: Historically, complication rates following
colorectal surgery were stratified by disease process, type
of operation, or anesthesia risk derived after an intensive
review of the medical record. Newer computer applica-
tions purport to shorten this process and predict the
probability of postoperative complications by distin-
guishing them from comorbidities that are co-mingled on
uniform discharge codes. We analyzed CaduCIS software
(CareScience, Inc., Philadelphia, PA) which uses dis-
charge codes to see if its predictions of comorbidity and
complications accurately track the medical record.
METHODS: Two-hundred and seventy patients were an-
alyzed using principal and secondary diagnoses coded on
discharge. Coding inaccuracies of clinical occurrences
were identified by physician review of each medical
record. The actual incidences of 17 common preoperative
comorbidities and 11 postoperative complications were
compared to computerized predictions by applying stan-
dard statistical tests. RESULTS: The overall incidence of
complications obtained by physician (actual) review was
47%, compared to 46% by computer. The computerized
predicted distribution of comorbidities was similar to the
actual occurrences in 15 of 17 categories. Analysis
showed a statistical difference between the computer-pre-
dicted and “actual” complication rates in 5 of the 11 cat-
egories; however these differences (underestimates) were
due to charting and coding inaccuracies, not to comput-
erized errors. The most common preoperative comorbidi-
ties and complications were cardiopulmonary (47% and
28%, respectively). CONCLUSIONS: The computer-sys-
tem’s accurate measurement of the overall complication
rate supports the claim that aggregate complication esti-
mates derived from readily available administrative data
are sufficient for across-the-board comparisons among
hospitals. The computerized system can generate such
measurements in a fraction of the time is takes to manu-
ally review the medical records. As uniform discharge
coding of co-mingled comorbidity and complications are
increasingly used to rapidly compute surgical outcomes,
colon and rectal surgeons need to ensure compatibility of
the actual and coded medical record.
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OBJECTIVES: Infliximab (Remicade) (I) 5mg/kg is effec-
tive to control refractory Crohn’s disease in 81% and to
improve fistulas in 68% of patients, thus greatly improv-
ing quality of life (QoL). The objective of this study was
to calculate the direct costs and savings generated by I to
achieve this improvement of QoL. METHODS: This mir-
ror-image study was carried out in 48 patients, of which
22 had fistulas, all responding to therapy. Patients were
followed for 6 to 24 months prior and 6 to 24 months af-
ter I. All direct costs to the Belgian public payer were re-
corded separately for every 6 month time period before
and after I, in order to control for a bias due to changed
management regardless of I. The cost of I was calculated
separately. IBDQ scores were recorded before and after I
for each period. RESULTS: There was an important
build up of costs in each period before I: 2–1.5y: 1,002
(459) Euro; 1.5–1.0y: 1,486 (459) Euro; 1.0–0.5:
2,114 (391) Euro; 0.5–0: 2,427 (302) Euro. After I
there was a sharp decrease of the cost of care (excluding
the cost of I) to 1,760 (239) Euro (00.5y) and 1,380
(264) Euro (0.51.0y). The decrease was statistically
significant (p0.016). The average cost of I in the first
six months was 4,850 (327) Euro and in the second six
months 1,300 (280) Euro. The IBDQ increased from
147.8 (SE 8.4) to 187.8 (SE 7.0). The total direct cost of
care after I, adjusted for the non-responders, was calcu-
lated to be 17.0 Euro per day of normalised QoL. CON-
CLUSIONS: Although the cost of infliximab is substan-
tial, the total direct cost to produce a normal QoL in the
entire year after therapy is quite acceptable, providing
that patients not responding are not further treated.
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Health-related quality of life (HRQoL) research suggests
that, due to unique characteristics of a disease state, dis-
ease specific tools are better discriminators of health sta-
tus than generic tools. OBJECTIVE: To compare generic
(SF-12) versus disease specific (SIBDQ) quality of life
tools in a cohort of patients receiving treatment for
Crohn’s Disease (CD). METHODS: Structural Equation
